Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946192 · ClinicalTrials.gov registry record · Phase 3
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT00946192: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00946192 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 121 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00946192, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes. The second aim of this study is to determine whether transdermal or oral estrogen (versus no estrogen) is effective in increasing bone density and improving bone microarchitecture in adolescent athletes who are not getting their periods and are thus estrogen deficient. The investigators hypothesize that transdermal estrogen will be more effective than oral estrogen or no estrogen in improving bone health in amenorrheic adolescent athletes.
Interventions
- DRUG Transdermal 17Beta-estradiol, progesterone
- DRUG Ethinyl Estradiol + Desogestrel
- DIETARY_SUPPLEMENT Sham Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2009-05 |
| Est. Completion | 2021-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946192
The ClinicalTrials.gov registry entry for NCT00946192 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Transdermal 17Beta-estradiol, progesterone is the first listed.
NCT00946192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946192 about?
NCT00946192 is a clinical study titled "Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes". One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes. The second aim of this study is to determine whether transdermal or oral estrogen (versus no estr...
What is the current status of trial NCT00946192?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2009-05. Estimated completion is 2021-04.
What interventions are being tested in trial NCT00946192?
The interventions under investigation include: Transdermal 17Beta-estradiol, progesterone (DRUG), Ethinyl Estradiol + Desogestrel (DRUG), Sham Comparator (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00946192?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.